role

Avian (Bird) Flu: Is There a Role for Rapid Tests?

With human infections of bird flu (avian influenza) reported in Asia and Eastern Europe, public health officials have moved swiftly to develop policies on surveillance, diagnosis, and treatment. The virus in question is the H5N1 subtype of influenza A, which has become epidemic...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced results of secondary endpoint data from its 99patient, randomized, placebo-controlled, multi-center Phase IIbtrial (DLXLEF-AP4) with...

Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression

Findings Published in Molecular Cell Show Potential of microRNAs asNovel Cancer Drug Targets REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 05, 2007/PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading microRNAcompany, announced today research published in the journalMolecular Cell by scientists from the Weizmann Institute of Scienceand Rosetta Genomics . The findings suggest...

Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action

SALT LAKE CITY, June 14, 2007 /PRNewswire/ -- ProlexysPharmaceuticals and announced today a publication describing theproperties of the selective small molecule anti-tumor agent,erastin. Prolexys and Columbia applied the company'schemi-proteomics technology to understand the mechanism of actionof erastin. The results, to be published in the June 14, 2007 issueof the journal Nature reveal...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential fornew option to improve convenience for patients - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today announced the presentation of positivedata for VELCADE, the market-leading therapy for patients withmultiple myeloma (MM) who have received at least one prior therapy.These data include resu...

Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients

* Treatment with ISIS 301012 produced at least 45% additionalreduction in patients' LDL-cholesterol when added tomaximally-tolerated lipid-lowering therapies CARLSBAD, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- IsisPharmaceuticals, Inc. announced updated results from its ongoingPhase 2 clinical trial of ISIS 301012 in patients with homozygousfamilial hypercholesterolemia (HoFH), initi...

YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain

MISSISSAUGA, ON, May 02, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced top-line results from its randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) in opioid naivepatients with post-operative pain following orthopedic surgery.AeroLEF(TM) met the pr...

Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - AeolusPharmaceuticals, Inc. (OTCBB:AOLS) announced the presentation ofdata by researchers at Loma Linda University Medical Center showingthat one of the Company's metalloporphyrin antioxidants, AEOL10113, may play an important role regulating the oxidative damageinduced by ionizing radiation. Radiation therapy is used alone or in comb...

MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases

- Preclinical Data Support Rationale for Targeting Pro-InflammatoryProtein - GAITHERSBURG, Md., April 18, 2007 /PRNewswire-FirstCall/ --MedImmune, Inc. today announced the publication of preclinicalstudy data demonstrating a role for high mobility group boxprotein-1 (HMGB1), a nuclear DNA-binding protein, in the pathologyof systemic autoimmune diseases such as systemic lupuserythematosus...

Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, announced results from two pre-clinical studies thatsupport the role of SPARC (secreted protein acidic and rich incysteine) expression in cancer and Abraxis' nanoparticlealbumin-bound (nab(TM)) tumor-targeting technology at the 98thAmerican Association for Canc...

Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa

'Off' Time Reduced By an Average of More Than Two Hours Per Day RESEARCH TRIANGLE PARK, N.C., April 02, 2007 /PRNewswire/ --Adding the once daily, investigational medication REQUIP(R)(ropinirole HCl) XL 24-Hour(TM) Extended-Release Tablets toParkinson's patients' existing levodopa (L-dopa) therapysignificantly reduced 'off' time, allowing patients to continuetheir daily activities for a l...

New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis

Majority of Infants Infected by Members of Their Own Household SWIFTWATER, Pa., March 27, 2007 /PRNewswire/ -- A new studyreleased today in the April issue of The Pediatric InfectiousDisease Journal about the transmission of pertussis -- commonlyknown as whooping cough -- found that household members were thesource for 71 to 82 percent of cases among infants for whom asource case could be...

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients Presented at ACC

* Homozygous FH patients already being treated with maximallytolerated lipid-lowering therapies experienced 50% furtherreductions in LDL-C with similar reductions in other atherogenicwhen treated with 300 mg/week ISIS 301012 NEW ORLEANS, and CARLSBAD, Calif., March 26, 2007/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announcedresults from its ongoing Phase 2 clinical trial of ISIS...

Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 22, 2007 - AlnylamPharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeuticscompany, announced today publication of a study in the journal Cellby Alnylam and Stanford University scientists on the role of miRNAsin immunity. In the pre-clinical study, a specific miRNA, miR-181a,was shown to play an important role in controlling T cellresponsivenes...

JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program

PALO ALTO, Calif., March 14, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that the Journal of the ofCardiology (JACC) has published data from the Ranolazine Open LabelExperience (ROLE) program, which showed long-term therapy withRanexa(R) (ranolazine extended-release tablets) to be safe and welltolerated in patients with chronic stable angina who completed oneof tw...

Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences,Inc., a specialty dermatology company, today announced thepublication of a paper in the March 9, 2007 issue of the journalCell by its co-founder and board member, David E. Fisher, M.D.,Ph.D., that identifies two new functions for an important protein,p53, in the pigmentation of skin. Fisher's study shows that inaddition to i...